Have a feature idea you'd love to see implemented?
Let us know!
PCVX Vaxcyte Inc
Price (delayed)
$88.39
Market cap
$11.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.6
Enterprise value
$9.99B
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious
Highlights
Vaxcyte's equity has surged by 144% YoY and by 72% QoQ
PCVX's quick ratio is up by 19% year-on-year
The debt has surged by 102% year-on-year and by 9% since the previous quarter
The net income has plunged by 69% YoY and by 2.1% from the previous quarter
Key stats
What are the main financial stats of PCVX
Market
Valuations
Earnings
Shares outstanding
124.64M
Market cap
$11.02B
Enterprise value
$9.99B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.89
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$507.65M
EBITDA
-$493.64M
Free cash flow
-$616.24M
Per share
Balance sheet
Liquidity
EPS
-$4.6
Free cash flow per share
-$4.98
Book value per share
$30.62
Revenue per share
$0
TBVPS
$28.78
Total assets
$3.56B
Total liabilities
$142.11M
Debt
$27.96M
Equity
$3.42B
Working capital
$2.09B
Debt to equity
0.01
Current ratio
17.88
Quick ratio
17.61
Net debt/EBITDA
2.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-22.2%
Return on equity
-23.5%
Return on invested capital
-32.5%
Return on capital employed
-14.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCVX stock price
How has the Vaxcyte stock price performed over time
Intraday
2.83%
1 week
-4.63%
1 month
-23.44%
1 year
74.13%
YTD
40.75%
QTD
-22.65%
Financial performance
How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$604.05M
Net income
-$507.65M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has shrunk by 69% YoY and by 4.7% QoQ
The net income has plunged by 69% YoY and by 2.1% from the previous quarter
Growth
What is Vaxcyte's growth rate over time
Valuation
What is Vaxcyte stock price valuation
P/E
N/A
P/B
2.89
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 38% YoY
Vaxcyte's equity has surged by 144% YoY and by 72% QoQ
The P/B is 30% lower than the last 4 quarters average of 4.1 and 28% lower than the 5-year quarterly average of 4.0
Efficiency
How efficient is Vaxcyte business performance
PCVX's ROIC is up by 31% year-on-year and by 23% since the previous quarter
Vaxcyte's return on equity has increased by 22% QoQ and by 7% YoY
PCVX's ROA is up by 21% QoQ and by 7% YoY
Dividends
What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCVX.
Financial health
How did Vaxcyte financials performed over time
The company's total assets has surged by 138% YoY and by 71% QoQ
The total liabilities has surged by 52% year-on-year and by 41% since the previous quarter
The debt is 99% smaller than the equity
Vaxcyte's equity has surged by 144% YoY and by 72% QoQ
The debt has surged by 102% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.